i3 Membrane continues its international expansion with the establishment of i3 Membrane Limited, headquartered in Manchester, United Kingdom. This step will strengthen our presence in the UK market as we continue to pursue our growth strategy in infection prevention and life science filtration.
“The UK is a key market for i3 Membrane, with a strong commitment to infection prevention and patient safety,” says Adam Dakri, CEO at i3 Membrane Ltd. “Establishing a local presence allows us to work closely with healthcare professionals, better understand national requirements, and support the effective use of Point-of-Use filtration to help reduce the risk of waterborne infections.
According to the World Health Organization’s 2025 Global Antibiotic Resistance Surveillance Report, antimicrobial resistance continues to rise globally, with data from more than 104 countries showing widespread and increasing resistance to commonly used antibiotics; in 2023, approximately one in six laboratory-confirmed bacterial infections was resistant to antibiotic treatment.
“We know that establishing a reliable barrier, particularly against gram-negative, water-associated bacteria, is a key element in preventing the spread of resistant pathogens,” says Dr. Stephan Brinke-Seiferth, CEO of i3 Membrane GmbH. “Numerous studies provide strong evidence, and we believe that Point-of-Use sterilizing grade filters can make a significant contribution to improving patient safety.”
We very much look forward to close collaboration and knowledge exchange with UK healthcare professionals, hygiene experts, and institutions, as well as to building strong local partnerships. Together, we aim to contribute to safer environments in medical and other sensitive settings.